N-({(5S)-3-[3-氟-4-(三甲基锡烷基)苯基]-2-氧代-1,3-恶唑烷-5-基}甲基)乙酰胺 | 188975-86-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-({(5S)-3-[3-氟-4-(三甲基锡烷基)苯基]-2-氧代-1,3-恶唑烷-5-基}甲基)乙酰胺
• 中文别名: N-[(5S)-3-(3-氟-4-三甲基锡烷基苯基)-2-羰基-噁唑烷-5-基甲基]乙酰胺
• 英文名称: N-({(5S)-3-[3-fluoro-4-(trimethylstannyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
• 英文别名: (S)-(-)-N-[[3-[4-trimethylstannyl-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide；N-({3-[3-fluoro-4-(tromethylstannyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide；(5S)-3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-(acetamidomethyl)-1,3-oxazolidin-2-one；(S)-N-[[3-[3-fluoro-4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide；N-[5(S)-3-[3-fluoro-4-(trimethylstannyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide；(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide；N-[[(5S)-3-(3-fluoro-4-trimethylstannylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 188975-86-2
• 化学式: C₁₅H₂₁FN₂O₃Sn
• 分子量: 415.052
• InChiKey: RBAABWDVPFMSIL-HZAYLZKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.83
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-acetoxyacetylamino-5-bromopyridine 、 N-({(5S)-3-[3-氟-4-(三甲基锡烷基)苯基]-2-氧代-1,3-恶唑烷-5-基}甲基)乙酰胺 以 N-甲基乙酰胺 、 水 、 三乙胺 为溶剂， 生成 (S)-[N-3-(4-(2-acetoxyacetylaminopyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
  参考文献：
  名称：

  Novel oxazolidinone derivatives and a process for the preparation thereof

  摘要：

  本发明涉及新颖的噁唑烷酮衍生物，其药用盐以及其制备方法。更具体地，本发明涉及在苯环的4位被杂环和杂芳环取代的噁唑烷酮衍生物。本发明的化合物具有广泛的抗菌谱、优越的抗菌活性和低毒性，因此本发明的化合物可用作抗菌剂。

  公开号：

  US20030166620A1
• 作为产物：
  描述：

  (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨 在 六甲基二锡 作用下， 以 1,4-二氧六环 、 dichlorobis(triphenylphosphine)palladium[II] 为溶剂， 生成 N-({(5S)-3-[3-氟-4-(三甲基锡烷基)苯基]-2-氧代-1,3-恶唑烷-5-基}甲基)乙酰胺
  参考文献：
  名称：

  Novel oxazolidinone derivatives and a process for the preparation thereof

  摘要：

  本发明涉及新颖的噁唑烷酮衍生物，其药用盐以及其制备方法。更具体地，本发明涉及在苯环的4位被杂环和杂芳环取代的噁唑烷酮衍生物。本发明的化合物具有广泛的抗菌谱、优越的抗菌活性和低毒性，因此本发明的化合物可用作抗菌剂。

  公开号：

  US20030166620A1

文献信息

• [EN] OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTERIENS
  申请人：ASTRAZENECA AB

  公开号：WO2004056817A1

  公开（公告）日：2004-07-08

  A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: (I)wherein in (I) C is for example wherein A and B are independently selected from i) ii) and m is 1 or 2;R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me;R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me;R1a is for example optionally substituted (1-10C)alkyl;R1b is for example selected from NR5C(=W)R4, a) , or b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl.Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.

  公式（I）的化合物，或其药学上可接受的盐，或其中的体内水解酯：（I）其中在（I）中，C例如，其中A和B分别选择自i）ii）和m为1或2；R2b和R6b，R2a和R6a，R3a和R5a，例如选择自H，F，OMe和Me；R2b'和R6b'，R2a'和R6a'，R3a'，R5a'例如选择自H，OMe和Me；R1a例如是可选取代的（1-10C）烷基；R1b例如选择自NR5C（=W）R4，a），或b）其中HET-1例如为异噁唑基，HET-2例如为三唑基或四唑基。还描述了制备公式（I）的化合物的方法，含有它们的组合物以及它们作为抗菌剂的用途。
• [EN] NOVEL OXAZOLIDINONE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'OXAZOLIDINONE
  申请人：DONG A PHARM CO LTD

  公开号：WO2005058886A1

  公开（公告）日：2005-06-30

  The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.

  本发明涉及新型氧唑啉酮衍生物，其方法以及包含这些衍生物的制药组合物，用于抗生素。本发明的氧唑啉酮衍生物显示出对广谱细菌的抑制活性和较低的毒性。通过将具有羟基的化合物与氨基酸或磷酸反应制备的前药，在其溶解度对水表现出优异效率。此外，本发明的衍生物可能对各种人类和动物病原体发挥强效的抗菌活性，包括革兰氏阳性细菌如葡萄球菌、肠球菌和链球菌，厌氧微生物如拟杆菌和梭菌，以及耐酸微生物如结核分枝杆菌和分枝杆菌。因此，含有氧唑啉酮的组合物用作抗生素。
• Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring
  作者：Yeong Woo Jo、Weon Bin Im、Jae Keol Rhee、Mi Ja Shim、Won Bae Kim、Eung Chil Choi

  DOI：10.1016/j.bmc.2004.08.025

  日期：2004.11

  group of linezolid was replaced with heteroaromatic ring substituted pyridine moiety, were newly synthesized, and their substituted effects on in vitro and in vivo antibacterial activities were evaluated against four problematic gram-positive strains including drug resistant strains and two gram-negative strains. Most compounds exhibited the enhanced in vitro activities with 4-16-fold and three compounds

  新合成了一系列恶唑烷酮衍生物，其中的利奈唑胺的吗啉代基团被杂芳环取代的吡啶部分取代，并评估了它们对四种有问题的革兰氏阳性菌株的体外和体内抗菌活性的取代作用，包括耐药菌株和两个革兰氏阴性菌株。大多数化合物具有4-16倍的增强的体外活性，三种化合物的体内功效比利奈唑胺高2倍以上。
• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE A ACTIVITE ANTIMICROBIENNE
  申请人：RANBAXY LAB LTD

  公开号：WO2006035283A1

  公开（公告）日：2006-04-06

  The present invention relates to substituted phenyl oxazolidinones and processes for preparing thereof. This invention also relates to pharmaceutical compositions comprising compounds of the present invention. Such compounds can be useful antimicrobial agents that can be particularly effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria (e.g., multiple-resistant staphylococci, streptococci and enterococci), anaerobic organisms (e.g., Bacterioides spp. and Clostridia spp. species), and acid-fast organisms (e.g., Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp).Formula (I).

  本发明涉及取代苯基噁唑烷酮及其制备方法。本发明还涉及包含本发明化合物的药物组合物。这些化合物可以是有用的抗微生物剂，特别是对许多人类和兽医病原体具有特效，包括革兰氏阳性厌氧细菌（例如，多耐药葡萄球菌、链球菌和肠球菌）、厌氧菌（例如，拟杆菌属和梭菌属物种）和耐酸菌（例如，结核分枝杆菌、分枝杆菌和分枝杆菌属）。公式（I）。
• Tropone-substituted phenyloxazolidinone antibacterial agents
  申请人：The Upjohn Company

  公开号：US05523403A1

  公开（公告）日：1996-06-04

  A novel class of phenyloxazolidinone antibacterial agents which have, as their salient structural feature, an appended substituted tropone moiety, are described. Intermediates and processes for the preparation of these antibiotics are also disclosed. These compounds are useful antibacterial agents to eradicate or control susceptible organisms. ##STR1## wherein R.sup.4 is oxygen substituted heptatrienyl and R.sup.1, R.sup.2, and R.sup.3 are as defined herein.

  本文描述了一种新型的苯氧唑啉类抗菌剂，其显著的结构特征是附加了取代的茚酮基团。同时还公开了这些抗生素的中间体和制备方法。这些化合物是有用的抗菌剂，可根除或控制易感染的微生物。其中，R4为氧取代的七环共轭三烯基，R1、R2和R3如本文所定义。